Scientists tested a new nano-formulation of the antifungal drug amphotericin B against a dangerous fungus (Rhizopus arrhizus) that infected COVID-19 patients with mucormycosis. The nanoliposomal version of the drug worked much better than regular amphotericin B and other antifungal medications currently used, showing much lower concentrations needed to kill the fungus. This research suggests the new nano-formulation could be a more effective treatment option for patients with this serious COVID-19 related fungal infection.